

Colchicine Averts Postpericardiotomy Syndrome

BY MITCHEL L. ZOLER

FROM THE ANNUAL CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY

STOCKHOLM – Daily, prophylactic treatment with colchicine for 1 month following cardiac surgery safely cut the incidence of postpericardiotomy syndrome by more than half in a placebo-controlled trial with 360 patients, the first large, controlled trial to ever assess a treatment for this common, post-surgical complication.

“Colchicine is safe and effective for the primary prevention of PPS [postpericardiotomy syndrome] and its related complications,” Dr. Massimo Imazio said at the annual Congress of the European Society of Cardiology. “The main limitation of the study is the lack of standardized criteria for diagnosing PPS,” which means that some patients counted as developing PPS may have had a mild form of the syndrome. Notably, the study constituted the first attempt to apply objective PPS diagnostic criteria, said Dr. Imazio, a cardiologist at Maria Vittoria Hospital in Torino, Italy.

The study employed a “simple and sound methodology,” and finding that colchicine treatment prevented one episode of PPS for every eight cardiac surgery patients treated, the number needed to treat, “is very good,” commented Dr. Andre Keren, professor of medicine and director of the Heart Failure and Heart Muscle Disease Center at Hadassah University Hospital in Jerusalem. The new study “was a carefully performed trial in which colchicine provided effective and safe treatment,” Dr. Keren said.

Results from prior reports indicated that 10%-40% of all patients undergoing cardiac surgery developed PPS. The new findings supported that, with a PPS incidence of 21% among patients in the placebo group followed for 12 months. In addition, 85% of all PPS cases occurred during the first 30 days following surgery, a finding that prompted Dr. Imazio to recommend limiting colchicine treatment to the first post-operative month.

The Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) trial enrolled patients aged 18 years or older who underwent cardiac surgery. Their average age was 66, and two-thirds were men. Enrolled patients most frequently had undergone isolated coronary artery bypass grafting, in 47%, followed by isolated valve surgery, in 30%, a combined procedure, in 19%, isolated aortic surgery in 3%, and other types of surgery making up the remaining cases.

Starting on the third day after surgery, patients received either 1 mg oral colchicine b.i.d. for 1 day followed by 0.5 mg b.i.d. or placebo for 29 days. Patients weighing less than 70 kg received 0.5 mg b.i.d. on the first postoperative day followed by 0.5 mg daily for 29 days.

The researchers diagnosed PPS when patients developed at least two of the following conditions during follow-up: a

fever lasting longer than the first post-operative week with no evidence of systemic or local infection, pleuritic chest pain, friction rub, pleural effusion, or new or worsening pericardial effusion.

During the first 12 months after surgery, 38 of the 180 placebo patients, 21%, developed PPS by these criteria compared with 16 patients in the colchicine arm, 9%, a statistically significant difference. Pleural effusion oc-

curred most often, in 26% of the placebo patients and in 12% of those on colchicine, followed by new or worsening pericardial effusion, in 23% of placebo patients and 13% in the active-treatment arm.

No patient in the study developed a serious side effect. Side effects, most often gastrointestinal intolerance, occurred in 5% of placebo patients and in 9% on colchicine, a nonsignificant difference. GI

intolerance is a well-established adverse effect of colchicine.

Until now, colchicine, a generic anti-inflammatory drug, has primarily been known as a treatment for gouty arthritis. The study did not receive commercial funding, but Acaripa, a Portuguese company, supplied the colchicine and placebo tablets used in the study. Dr. Imazio said that he and his associates had no disclosures. ■



TIKOSYN can help put your atrial fibrillation/atrial flutter patients back into normal sinus rhythm and keep them there

- At the 500 mcg BID dosage, TIKOSYN converted 30% of patients to normal sinus rhythm (NSR) vs 1% conversion with placebo¹
- The probability of patients on TIKOSYN 500 mcg BID remaining in NSR at 12 months was 58% compared with 25% for the patients given placebo ($P=.001$)²
- TIKOSYN is a Class III antiarrhythmic that has been in clinical use for over 10 years^{1,3}

In order to prescribe TIKOSYN you must be trained and certified. Here's how:

- Visit www.TIKOSYN.com to view the product monograph and certification materials, or
- Call 1-877-TIKOSYN (845-6796) to request all certification materials be mailed

For additional information, please visit www.TIKOSYN.com

TIKOSYN[®] 500
250
125
mcg
capsules
(dofetilide)

IMPORTANT SAFETY INFORMATION

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.

TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFI]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life-threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients.

TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.

TIKOSYN is contraindicated in patients with congenital or acquired long QT syndromes, a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities), severe renal impairment (calculated creatinine clearance <20 mL/min), or known hypersensitivity to TIKOSYN.

TIKOSYN is also contraindicated with verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), and cation transport system inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, and megestrol because these drugs may cause an increase in dofetilide plasma concentration.

TIKOSYN can cause serious ventricular arrhythmias, primarily torsade de pointes type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. QT interval prolongation is directly related to dofetilide plasma concentrations. Factors such as reduced creatinine clearance or certain dofetilide drug interactions will increase dofetilide plasma concentration. The risk of TdP can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval. Calculation of creatinine clearance and QTc for all patients must precede administration of the first dose of TIKOSYN. Renal function and QTc should be re-evaluated every 3 months or as medically warranted.

The most common adverse events reported were headache, chest pain, dizziness, respiratory tract infection, dyspnea, and nausea.

Please see TIKOSYN Brief Summary of Prescribing Information on following pages.

References: 1. TIKOSYN Prescribing Information. New York, NY: Pfizer Inc; 2006. 2. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. *Circulation*. 2000;102:2385-2390. 3. Drugs@FDA. Drug Details. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails>. Accessed July 7, 2010.